Filamin A Mutations: A New Cause of Unexplained Emphysema in Adults?


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
03 2021
Historique:
received: 20 05 2020
revised: 22 09 2020
accepted: 01 10 2020
entrez: 8 3 2021
pubmed: 9 3 2021
medline: 25 9 2021
Statut: ppublish

Résumé

Emphysema is a chronic respiratory disorder characterized by destruction of alveoli, usually due to cigarette smoking or exposure to noxious particles or gases. Dysfunction of proteins that are involved in lung development and maintenance, such as alpha-1 antitrypsin, also contributes to emphysema. Filamin A (FLNA) is an actin-binding protein involved in cytoskeleton reorganization. Mutations in the FLNA gene classically lead to abnormal neuronal migration and connective and vascular tissue anomalies. Pulmonary manifestations consist of a wide range of pulmonary disorders that occur during infancy. We report the first familial case of emphysema in non- and very low-smoking adults who carry a loss-of-function mutation of the FLNA gene. The identification of this new risk factor for emphysema encourages (1) screening, prevention and monitoring of pulmonary disorders in patients with FLNA mutation and (2) screening for FLNA mutation in patients with early-onset emphysema that is associated with low-smoking or vascular or connective tissue anomalies.

Identifiants

pubmed: 33678279
pii: S0012-3692(20)34884-4
doi: 10.1016/j.chest.2020.10.003
pii:
doi:

Substances chimiques

FLNA protein, human 0
Filamins 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e131-e135

Informations de copyright

Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Auteurs

Victor Valentin (V)

CHU de Lille, Service de Pneumologie et Immuno-allergologie, Centre de référence constitutif pour les maladies pulmonaires rares, Univ. Lille, Lille, France. Electronic address: victor.valentin@chru-lille.fr.

Jean-François Bervar (JF)

CHU de Lille, Service de Pneumologie et Immuno-allergologie, Centre de référence constitutif pour les maladies pulmonaires rares, Univ. Lille, Lille, France.

Catherine Vincent-Delorme (C)

CHU de Lille, Clinique de Génétique, Univ. Lille, Lille, France.

Thomas Smol (T)

CHU de Lille, Institut de Génétique, Univ. Lille, Lille, France.

Lidwine Wemeau (L)

CHU de Lille, Service de Pneumologie et Immuno-allergologie, Centre de référence constitutif pour les maladies pulmonaires rares, Univ. Lille, Lille, France.

Martine Remy (M)

CHU de Lille, Department of Thoracic Imaging, Hospital Calmette, Univ. Lille, Lille, France.

Olivier Le Rouzic (O)

CHU de Lille, Service de Pneumologie et Immuno-allergologie, Centre de référence constitutif pour les maladies pulmonaires rares, Univ. Lille, Lille, France.

Cécile Chenivesse (C)

CHU de Lille, Service de Pneumologie et Immuno-allergologie, Centre de référence constitutif pour les maladies pulmonaires rares, Univ. Lille, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH